

AngioDynamics to Rename Laser Venous System

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Aug. 5, 2004--AngioDynamics, Inc., (Nasdaq:ANGO) today announced that it is changing the name of its endovascular laser venous system to VenaCure™ Laser Vein Treatment. To support the change, the Company is launching a new web site www.venacure.com along with updated marketing materials.

VenaCure is a minimally invasive alternative for the treatment of severe varicose veins. The procedure lasts about 45 minutes and offers patients an effective out-patient alternative to surgical ligation and vein stripping.

AngioDynamics developed the name VenaCure as a way to establish name recognition for the products used in a procedure that is becoming more and more popular with patients as well as doctors. The Company will use the patient friendly name in conjunction with its marketing welcome kit, to further assist physicians in developing and marketing this aspect of their practice.

The current kit, an all-inclusive marketing package, recently received the "Award of Excellence" in the Dealer/Distributor Materials Category at the 29th Annual Pro-Comm Awards -- the longest running and most respected business-to-business marketing communications awards program in the U.S.

Commenting for AngioDynamics, Product Manager David Doster, said, "We are excited to launch the new VenaCure brand name, a change that reflects our ongoing commitment to increase public awareness of this important procedure. Through programs like the new VenaCure web site and our award-winning 'business in a box' welcome kit, we will continue to support physicians who partner with us with patient information and services."

For additional information on the VenaCure Laser Vein Treatment, contact David Doster at 1-800-772-6446, ext. 126, Email: DDoster@angiodynamics.com. You may also visit either the laser treatment web site at www.venacure.com or the AngioDynamics web site at www.angiodynamics.com.

About AngioDynamics

AngioDynamics, Inc. (www.angiodynamics.com) designs, develops, manufactures and markets innovative medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease. It offers a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. AngioDynamics' diversified product line includes angiographic catheters, hemodialysis catheters, PTA dilation catheters, thrombolytic products, image-guided vascular access products, endovascular laser venous system products, as well as drainage products. AngioDynamics is a majority-owned subsidiary of E-Z-EM, Inc. (AMEX:EZM), a leading manufacturer of contrast agents for gastrointestinal radiology.

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, market acceptance and future sales of the VenaCure™ Laser Vein Treatment System, results of the pending patent litigation with Diomed, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, including alternative procedures which continue to replace traditional fluoroscopic procedures, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics Inc., including but not limited to its Registration Statement on Form S-1, may affect the actual results achieved by the Company.

CONTACT: AngioDynamics, Inc.
Lisa Donegan, 800-772-6446 x370
<http://www.angiodynamics.com/>
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz (kgolodetz@lhai.com)
212-838-3777

Bruce Voss (bvoss@lhai.com)
310-691-7100

SOURCE: AngioDynamics, Inc.